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Cardiopulmonary exercise testing reflects
similar pathophysiology and disease
severity in heart failure patients with
reduced and preserved ejection fraction
Marco Guazzi1, Valentina Labate1, Lawrence P Cahalin2 and
Ross Arena3
Abstract
Background: We are unaware of any previous investigation that has compared the relationship of key cardiopulmonary
exercise testing (CPX) variables to various measures of pathophysiology between heart failure-reduced ejection fraction
(HFrEF) and HF-preserved ejection fraction (HFpEF) cohorts that are well matched with respect to baseline character-
istics and their exercise response, which is the purpose of the present study.
Methods: Thirty-four patients with HFpEF were randomly matched to 34 subjects with HFrEF according to age and sex
as well as peak oxygen consumption (VO2), ventilatory efficiency (VE/VCO2 slope), and exercise oscillatory ventilation
(EOV). In addition to CPX, patients also underwent echocardiography with tissue Doppler imaging (TDI) and assessment
of N-terminal pro-B-type natriuretic peptide (NT-proBNP).
Results: When matched for age, sex, and CPX variables, the HFrEF and HFpEF cohorts had similar echocardiography
with TDI and NT-proBNP values, indicating comparable disease severity. In addition, the correlations between key CPX
measures (peak VO2 and VE/VCO2 slope) and echocardiography with TDI and NT-proBNP measures were similar
between HFrEF and HFpEF groups. Of note, the correlation between the VE/VCO2 slope and pulmonary artery systolic
pressure and NT-proBNP was highly significant in both groups (r 0.65, p< 0.01). Moreover, subjects with EOV in both
groups had a significantly higher PASP (47 vs. 35 mmHg, p< 0.05).
Conclusions: The results of the current study indicate CPX equally represents disease severity in HFrEF and HFpEF
patients. This is a novel finding supporting the key role of CPX in the clinical follow-up of HF patients irrespective of LVEF
and cardiac phenotype.
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Introduction
Cardiopulmonary exercise testing (CPX) has convin-
cingly demonstrated the ability to predict adverse
events and reﬂect disease severity in patients with
heart failure-reduced ejection fraction (HFrEF).1–3
Peak oxygen consumption (VO2), the minute ventila-
tion/carbon dioxide production (VE/VCO2) slope, and
exercise oscillatory ventilation (EOV) have emerged as
core CPX variables in HFrEF. All three of these vari-
ables have consistently demonstrated strong prognostic
value. Moreover, as peak VO2 declines, VE/VCO2 slope
increases, and EOV becomes apparent, disease severity
clearly worsens.
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While the body of evidence demonstrating the ability
of CPX in HFrEF to reﬂect disease severity and prog-
nosis is robust, similar analyses in patients with HF-
preserved ejection fraction (HFpEF) are limited.
In recent years, however, investigations demonstrating
the clinical utility of CPX in HFpEF have begun to
emerge. Guazzi et al.4,5 demonstrated that VE/VCO2
slope and EOV both are signiﬁcant prognostic markers
in HFpEF. Moreover, there is initial evidence to indi-
cate CPX variables reﬂect disease severity in HFpEF.6
Moore et al.7 compared HFrEF and HFpEF cohorts
undergoing CPX and demonstrated a signiﬁcantly
higher peak VO2 and lower VE/VCO2 slope in the
latter group. Other investigations have also demon-
strated patients with HFpEF appear to have a more
favourable CPX response when compared to patients
with HFrEF.5 Given these diﬀerences between the CPX
responses of patients with HFrEF and HFpEF, ques-
tions remain with respect to the ability of CPX to reﬂect
pathophysiology in these two unique populations.
We are unaware of any previous investigation that
has compared the relationship of key CPX variables to
various measures of pathophysiology (i.e. LV and RV
cardiac performance indicators and brain natriuretic
peptide levels) between HFrEF and HFpEF cohorts
that are well matched with respect to baseline charac-
teristics and their exercise response, which is a primary
purpose of the present study. In patients with HFpEF
who present with a poor CPX response, further explor-
ation of pathophysiological mechanisms is needed.
In addition, this study addresses whether pathophysio-
logical mechanisms for CPX abnormalities are
comparable in patients with HFrEF and HFpEF. We
hypothesize that the pathophysiological mechanisms
for CPX abnormalities will be comparable in the
HFrEF and HFpEF cohorts, thus further support-
ing the clinical utility of CPX in the latter HF
population.
Methods
Subjects
Thirty-four patients with HFpEF (left ventricular ejec-
tion fraction, LVEF, 50%) were randomly matched
to 34 subjects with HFrEF (LVEF 40%). The HFrEF
database consisted of more than 150 subjects. Subjects
were matched according to the following factors: (1)
age within 5 years; (2) sex; (3) peak VO2 according to
Weber class;8 (4) VE/VCO2 slope according to ventila-
tory class;9 and (5) the presence or absence of exercise
oscillatory ventilation (EOV). Random matching
according to these ﬁve factors was performed while
blinded to the results of echocardiography with tissue
Doppler imaging (TDI) and the neurohormonal
analysis. None of the subjects in the HFpEF group
were receiving cardiac resynchronization therapy
(CRT) although 10% were in atrial ﬁbrillation. In the
HFrEF group, 25% were receiving CRT and 20% were
in atrial ﬁbrillation.
Echocardiography and TDI
An experienced echocardiographer performed the echo-
cardiographic analysis by transthoracic echocardiog-
raphy accomplished with an IE33 Philips ultrasound
unit (Andover, MD, USA), equipped with software
for TDI, using a 2.5–5.0MHz probe (S5). Standard
M-mode, 2D, and Doppler blood ﬂow measurements
were performed according to the current American
Society of Echocardiography Guidelines.10
TheTDI images of themitral annulusmovementwere
obtained from the apical 4-chamber view. A 1.5mm
sample volume was placed sequentially at the lateral
and septal annular sites. Analysis was performed for
the early (E0) diastolic peak velocities. Pulsed wave
Doppler echocardiography was used to assess mitral
peak early (E) wave ﬂow velocity. The ratio of early
transmitral ﬂow velocity to annular velocity (E/E0) was
considered as an index of end-diastolic pressure.11
Pulmonary artery systolic pressure (PASP) was esti-
mated by Doppler echocardiography from the systolic
right ventricular to right atrial pressure gradient using
the modiﬁed Bernoulli equation. Right atrial pressure
(clinically assessed jugular venous pressure) was added
to the calculated gradient to yield PASP. No subjects
had signiﬁcant right ventricular outﬂow tract
obstruction.
To obtain tricuspid annular plane systolic excursion
(TAPSE), the apical four-chamber view was used and
an M-mode cursor was placed through the lateral tri-
cuspid annulus in real time. Oﬄine, the brightness was
adjusted to maximize the contrast between the M-mode
signal arising from the tricuspid annulus and the
background. TAPSE was measured as the total dis-
placement of the tricuspid annulus (millimeters) from
end-diastole to end-systole, with values representing the
average TAPSE of three to ﬁve beats.
CPX procedures
Patients underwent an upright graded bicycle exercise
using a personalized ramp protocol. Heart rate was
continuously monitored by electrocardiography at rest
and during exercise. Blood pressure was measured
every 2 minutes and at peak exercise with a mercury
sphygmomanometer. Respiratory gas analysis was car-
ried out with a metabolic cart (Sensormedics Vmax29,
Yorba Linda, CA, USA) which was calibrated with a
standard gas of known concentration before each test.
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Minute ventilation (VE, body temperature, atmos-
pheric pressure saturated with water vapour), oxygen
uptake (VO2, standard temperature and pressure dry),
and carbon dioxide output (VCO2, standard tempera-
ture and pressure dry) were acquired breath-by-breath,
averaged over 30 seconds, and printed in rolling aver-
ages every 10 seconds. Peak VO2 and peak respiratory
exchange ratio (RER) were deﬁned as the highest
30-second averaged value obtained during exercise.
Ten-second averaged VE and VCO2 data, from the ini-
tiation of exercise to peak, were input into spreadsheet
software (Microsoft Excel, Microsoft Corp, Bellevue,
WA, USA) to calculate the VE/VCO2 slope via least
squares linear regression (y¼mxþ b, where m is slope).
Evidence from diﬀerent groups has convincingly shown
this method of calculating the VE/VCO2 slope to be
optimal for estimating prognosis.12,13 The occurrence
of EOV was deﬁned as an oscillatory pattern at rest
that persisted for 60% of the exercise test at an amp-
litude 15% of the average resting value.14 This ana-
lysis was carried out by a quite rapid manual
calculation.
Test termination criteria consisted of patient request,
ventricular tachycardia, 2.0mm of horizontal or
downsloping ST segment depression, or a drop in sys-
tolic blood pressure 20mmHg during progressive
exercise. A qualiﬁed exercise physiologist with phys-
ician supervision conducted each exercise test.
Blood sampling procedures and hormonal assays
All patients had a measurement of plasma N-terminal
pro-B-type natriuretic peptide (NT-pro-BNP) on the
same day before exercise. Venous blood samples were
obtained after at least 30 minutes of rest from an
indwelling catheter and collected in tubes containing
EDTA buﬀer. They were immediately placed on ice
and centrifuged at 4C. Plasma samples were stored
at 20C until assay. Blood samplings were obtained
10 minutes before CPET procedure, at peak exercise,
and 1 minute recovery phase.
Statistical analysis
A statistical software package (SPSS 19.0, Chicago, IL,
USA) was used to perform all analyses. With the excep-
tion of NT-proBNP, continuous and categorical data
are reported as mean standard deviation and percent-
ages, respectively. NT-proBNP is reported as median
and range due to skewed distribution. With the excep-
tion of NT-proBNP, paired t-testing compared key
continuous variables between HFrEF and HFpEF
groups. The Wilcoxon signed rank sum test compared
NT-proBNP values between HFrEF and HFpEF
groups. Chi-squared testing was used to compare
dichotomous data. Within HFrEF and HFpEF
groups, unpaired t-testing was used to compare CPX
and echocardiography with TDI variables while the
Mann–Whitney U test compared NT-proBNP accord-
ing to the presence or absence of EOV. Unpaired
t-testing also compared diﬀerences in peak VO2 and
VE/VCO2 slope in the HFrEF and HFpEF groups
according to EOV. Lastly, unpaired t-tests were used
to compare PASP according to the ventilatory classiﬁ-
cation system (classes I/II vs. III/IV).9 Pearson’s correl-
ation was used to assess the relationship between key
CPX variables and echocardiography with TDI meas-
urements as well as NT-proBNP in HFrEF and
HFpEF groups. Pearson’s correlation also assessed
the relationship between peak VO2 and VE/VCO2
slope in the HFrEF and HFpEF groups. Linear
and logistic regression was performed to examine pre-
dictors of peak VO2, VE/VCO2 slope, and EOV.
Multicollinearity diagnostics were performed to iden-
tify which independent variables to include in the
regression models due to the limited number of subjects
in each group. The results of multicollinearity diagnos-
tics reduced the number of independent variables to ﬁve
and included LVEF, PASP, TAPSE, E/E0, and peak
exercise NT-proBNP. These ﬁve independent variables
were used in all linear and logistic regression models.
Two separate logistic regression models examining pre-
dictors of EOV in patients with HFrEF and HFpEF
were developed. Two separate linear regression models
were developed to examine predictors of peak VO2 in
patients with HFrEF and HFpEF and two separate
linear regression models were developed to examine
predictors of the VE/VCO2 slope in patients with
HFrEF and HFpEF. A p-value <0.05 was considered
statistically signiﬁcant for all tests.
Results
Table 1 shows baseline subject characteristics as well as
the CPX response. With the exception of angiotensin-
converting enzyme inhibitor use, which was signiﬁ-
cantly higher in the HFrEF group, the two groups
were well matched.
Table 2 shows the diﬀerences in clinical, echocardi-
ography with TDI, and NT-proBNP variables between
HFrEF and HFpEF groups. As expected, LVEF was
signiﬁcantly greater in the HFpEF group. All other
variables in Table 2 were comparable between groups.
Table 3 shows the correlation results between pri-
mary continuous CPX variables (i.e. peak VO2 and
VE/VCO2 slope) and echocardiography with TDI and
NT-proBNP variables. With the exception of LVEF,
which only correlated with peak VO2 in the HFpEF
group, all other correlations were signiﬁcant in both
groups. Moreover, the correlation between peak VO2
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and VE/VCO2 slope was signiﬁcant and strikingly simi-
lar in the HFrEF (r¼0.61, p< 0.001) and HFpEF
(r¼0.59, p< 0.001) groups.
Table 4 compares echocardiography with TDI and
NT-proBNP variables according to EOV in both
HFrEF and HFpEF groups. The diﬀerences according
to EOV were more frequently signiﬁcant in the HFrEF
group, although trends were similar in the HFpEF
group. Additionally, in the HFrEF group, subjects
with EOV had a signiﬁcantly lower peak VO2
(11.0 3.6 vs. 16.4 4.7mlkg1min1, p< 0.01) and
signiﬁcantly higher VE/VCO2 slope (40.2 11.1 vs.
31.0 5.1, p< 0.01) compared to subjects without
EOV. Likewise, in the HFpEF group, subjects with
EOV had a signiﬁcantly lower peak VO2 (10.5 3.2
vs. 16.6 5.6mlkg1min1, p< 0.01) and signiﬁcantly
higher VE/VCO2 slope (38.7 8.2 vs. 30.3 7.8,
p< 0.01) compared to subjects without EOV.
Diﬀerences in peak VO2 and VE/VCO2 slope according
to EOV were similar in HFrEF and HFpEF groups.
The results of logistic regression analyses found only
LVEF to be a signiﬁcant predictor of EOV in patients
with HFpEF (OR 1.24, 95% CI 1.005–1.541; p¼ 0.04)
and peak exercise NT-proBNP was a nearly signiﬁcant
predictor of EOV in patients with HFrEF (OR 1.002,
95% CI 1.000–1.005; p¼ 0.05).
The results of linear regression analyses of peak
VO2 and VE/VCO2 slope in patients with HFrEF
found only PASP to be a signiﬁcant predictor of
peak VO2 (model r
2¼ 0.45; standardized beta coeﬃ-
cient 0.620; p¼ 0.01) while PASP, E/E0, and peak
exercise NT-proBNP were signiﬁcant predictors of
the VE/VCO2 slope (model r
2¼ 0.80; standardized
beta coeﬃcients 0.439, 0.332, and 0.352; p¼ 0.004,
0.01, and 0.001, respectively). The results of linear
regression analyses of peak VO2 and VE/VCO2 slope
in patients with HFpEF found only LVEF to be a
signiﬁcant predictor of peak VO2 (model r
2¼ 0.43;
standardized beta coeﬃcient 0.305; p¼ 0.04) while
PASP and peak exercise NT-proBNP were signiﬁcant
predictors of the VE/VCO2 slope (model r
2¼ 0.88;
standardized beta coeﬃcients 0.599 and 0.515;
p¼ 0.000 and 0.000, respectively).
Figure 1 illustrates the diﬀerence in PASP according
to the ventilatory classiﬁcation system (i.e. VE/VCO2
slope  or >36) for the HFrEF and HFpEF groups.
In both groups, PASP was signiﬁcantly higher in sub-
jects with a VE/VCO2 slope >36 (HFrEF 33.7 7.2 vs.
48.8 11.4; HFpEF 32.2 7.5 vs. 55.6 9.5; p< 0.01).
Table 2. Differences in variables reflecting cardiac function and disease severity according to heart failure type
HFrEF (n¼ 34) HFpEF (n¼ 34) p-value
NYHA class 2.3 0.75 2.1 0.81 0.15
LVEF (%) 28.6 6.7 55.8 4.5 <0.001
PASP (mmHg) 39.0 11.4 40.4 13.9 0.40
TAPSE (mm) 17.5 2.9 17.6 3.3 0.93
E/E0 13.2 6.4 11.9 6.2 0.32
Resting NT-proBNP (pg/ml) 982.5 (5890.0) 735.5 (3490.0) 0.16
NT-proBNP at peak exercise (pg/ml) 1109.5 (6080.0) 782.5 (3601.0) 0.22
NT-proBNP post exercise (pg/ml) 1067.5 (6306.0) 735.0 (3672.0) 0.26
Values are mean SD or median (range).; E/E0, ratio of early transmitral flow velocity to annular velocity; HF, heart failure; LVEF, left ventricular ejection
fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; pEF,
preserved ejection fraction; rEF, reduced ejection fraction; TAPSE, tricuspid annular plane systolic excursion.
Table 1. Matching results according to key baseline and CPX
variables
HFrEF
(n¼ 34)
HFpEF
(n¼ 34) p-value
Age (years) 63.0 9.0 62.7 9.3 0.77
Sex (male) 76 76 1.00
HF aetiology (ischaemic) 65 62 0.72
Prescribed ACE inhibitor 88 74 <0.01
Prescribed beta-blocker 68 59 0.27
Peak VO2 (mlkg1min1) 14.3 5.0 14.3 5.6 0.98
Peak RER 1.06 0.10 1.08 0.11 0.28
VE/VCO2 slope 34.5 9.0 33.5 8.8 0.20
EOV 38 38 1.00
Values are mean SD or %.; ACE, angiotensin-converting enzyme; EOV,
exercise oscillatory ventilation; HF, heart failure; pEF, preserved ejection
fraction; rEF, reduced ejection fraction; RER, respiratory exchange ratio;
VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen
consumption.
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Discussion
Several CPX variables have consistently demonstrated
a strong ability to predict adverse events in patients
with HFrEF. The variables that have garnered the
greatest amount of attention as prognostic markers
to this point are peak VO2, VE/VCO2 slope, and
EOV.14–17 More recently, evidence has begun to
emerge demonstrating these CPX variables may well
deﬁne dyspnoea sensation18 and are also prognostic in
patients with HFpEF,4,5 although more work is needed
to verify these initial ﬁndings. In patients with HFrEF,
the strong prognostic value of these CPX variables is
attributable to their ability to reﬂect the degree of
pathophysiology associated with this chronic cardiac
condition.1,19–21 Because of these demonstrated rela-
tionships, CPX also has clinical utility as a gauge of
disease severity in the HFrEF population. The ability
of these CPX variables to reﬂect pathophysiology and
thus gauge disease severity in patients with HFpEF is
unclear. Previous research intimates that patients with
HFpEF who undergo CPX may have a more favour-
able CPX response compared to patients with HFrEF,
although both patient populations demonstrate an
abnormal response compared to apparently healthy
controls.5,7 These diﬀerences in the CPX response
may lead one to hypothesize that the relationship
between key exercise variables (i.e. peak VO2, VE/
VCO2 slope, and EOV) and other established markers
of pathophysiology associated with HF diﬀers between
patients with HFrEF and HFpEF. To our knowledge,
this is the ﬁrst investigation to match HFrEF and
HFpEF patients according to baseline characteristics
and the CPX response to determine if the relationships
Table 3. Correlation analysis between key variables according to heart failure type
HFrEF (n¼ 34) HFpEF (n¼ 34)
Peak VO2 VE/VCO2 slope Peak VO2
VE/VCO2
slope
LVEF 0.14 0.29 0.34* 0.12
PASP 0.64** 0.77** 0.54** 0.88**
TAPSE 0.34* 0.41* 0.38* 0.56**
E/E0 0.45** 0.76** 0.44** 0.59**
Resting NT-proBNP 0.44** 0.66** 0.54** 0.86**
NT-proBNP at peak exercise 0.45** 0.67** 0.56** 0.88**
NT-proBNP post exercise 0.42* 0.66** 0.56** 0.88**
Values are correlation coefficients. *p< 0.05. **p< 0.01; E/E0 , ratio of early transmitral flow velocity to annular velocity; HF,
heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PASP, pulmonary
artery systolic pressure; pEF, preserved ejection fraction; rEF, reduced ejection fraction; TAPSE, tricuspid annular plane systolic
excursion; VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen consumption.
Table 4. Comparison between key variables according to presence of exercise oscillatory ventilation in both heart failure groups
HFrEF (n¼ 34) HFpEF (n¼ 34)
No EOV (n¼ 21) EOV (n¼ 13) No EOV (n¼ 21) EOV (n¼ 13)
LVEF (%) 30.0 6.6 26.4 6.4 54.5 4.4 57.8 4.1*
PASP (mmHg) 34.4 7.7 46.5 12.6** 35.9 12.4 47.9 13.3*
TAPSE (mm) 18.6 2.6 15.8 2.6** 18.4 3.0 16.3 3.5
E/E0 10.8 3.4 17.1 8.2* 10.3 5.6 14.5 6.5
Resting NT-proBNP (pg/ml) 786.0 (1844.0) 1450.0 (5420.0)** 645.0 (3490.0) 1800.0 (2725.0)
NT-proBNP at peak exercise (pg/ml) 865.0 (2020.0) 1593.0 (5300.0)** 666.0 (3601.0) 1950.0 (2906.0)*
NT-proBNP post exercise (pg/ml) 840.0 (2051.0) 1570.0 (5510.0)** 657.0 (3672.0) 2000.0 (3000.0)*
Values are mean SD or median (range). *p< 0.05. **p< 0.01.; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; PASP, pulmonary artery systolic pressure; pEF, preserved ejection fraction; rEF, reduced ejection fraction; TAPSE,
tricuspid annular plane systolic excursion; VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen consumption.
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reﬂecting pathophysiology are comparable between
these unique cardiac populations. Our ﬁndings indicate
that key CPX variables do reﬂect pathophysiology and
thus disease severity associated with HFrEF and
HFpEF in a comparable fashion. This is strengthened
by the ﬁnding that even NT-proBNP levels at peak
exercise are quite similar in the two groups.
Moreover, the relationship amongst these key CPX
60
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Figure 1. Difference in pulmonary artery systolic pressure according to the ventilatory classification system for HF-reduced ejection
fraction (A) and HF-preserved ejection fraction (B).
Ventilatory classes: I, VE/VCO2 slope <30.0; II, VE/VCO2 slope 30–35.9; III, VE/VCO2 slope 36–44.9; IV, VE/VCO2 slope 45.0.
*p< 0.01
HF, heart failure; PASP, pulmonary artery systolic pressure; pEF, preserved ejection fraction; rEF, reduced ejection fraction.
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variables, well established in HFrEF, is likewise com-
parable in HFpEF. Collectively, the results of the
present study support the clinical utility of CPX as a
non-invasive, cost-eﬃcient indicator of disease severity
in HFpEF. This demonstrated relationship also lends
credence to the potential of CPX to become an import-
ant prognostic assessment tool in the HFpEF popula-
tion, which has recently been demonstrated in previous
investigations.4,5
Perhaps one of the most compelling ﬁndings in the
current study is the ability of an elevated VE/VCO2
slope and EOV to reﬂect an elevated pulmonary pres-
sure, the latter of which has been shown to be an
important prognostic maker in the HF population.22,23
Previous research has found PASP estimated by echo-
cardiography with TDI closely approximates invasive
measures,24 validating our approach to pulmonary
haemodynamic assessment and lending credence to
the hypothesis that an elevated VE/VCO2 slope and
EOV portend a higher likelihood of secondary pulmon-
ary hypertension. Given the demonstrated relationship
between an elevated VE/VCO2 slope and ventilation-
perfusion mismatching,25,26 as well as the relationship
between EOV and ﬂuctuations in pulmonary blood
ﬂow,27 it is not surprising they both are indicative of
elevated pulmonary pressures in HF. In this context,
the ability of VE/VCO2 slope and EOV to reﬂect this
disconcerting secondary consequence of HFrEF and
HFpEF has a high level of clinical value.
Previous research has suggested that the VE/VCO2
slope may be a better reﬂector of HF disease severity
compared to peak VO2.
1 The correlation analysis pre-
sented in Table 3 is consistent with previous research
making this comparison, both in patients with HFrEF
and HFpEF. The VE/VCO2 slope, while signiﬁcantly
correlated to peak VO2, is relatively independent of
subject eﬀort and uniquely reﬂects physiological pro-
cesses that diﬀer from aerobic capacity (e.g. ventila-
tion-perfusion mismatching). The relative eﬀort
independence and unique relationship to pathophysi-
ology in HF may be primary reasons why VE/VCO2
slope holds key advantages over peak VO2 as a primary
CPX variable, both as a prognostic marker and meas-
ure of disease severity. There is a rather compelling
body of research to support this view point in patients
with HFrEF, although the consensus is both VE/VCO2
slope and peak VO2 should be assessed in combination
to improve prognostic resolution.3 While the current
investigation supports a similar pattern in HFpEF
with respect to VE/VCO2 slope and peak VO2, future
research should be performed to conﬁrm these ﬁndings.
The relatively small sample size is an obvious limi-
tation to the current investigation. Moreover, there
were a limited number of female subjects included
in the current analysis, which should be addressed
in future investigations. Given the small sample size,
our linear and logistic regression analysis results
should be viewed as exploratory at this point, requiring
veriﬁcation in larger datasets before considering clinical
application. In addition, even though echocardiog-
raphy with TDI has been shown to accurately estimate
cardiopulmonary haemodynamics, inclusion of inva-
sive assessments of pulmonary pressure would have
strengthened the current investigation. Lastly, both
atrial ﬁbrillation and CRT have been shown to
impact exercise performance in patients with HF; the
former diminishing performance28 and the latter
improving performance.29 As described in the ﬁrst
paragraph of the methods section, diﬀerences in the
number of subjects with atrial ﬁbrillation and CRT
use existed between HFrEF and HFpEF groups.
These were not baseline characteristics we could control
for and thus should be addressed in future investiga-
tions. Despite these limitations, the relationships
demonstrated in the HFrEF cohort in this study are
consistent with previous investigations, which lend cre-
dence to our ﬁndings in subjects with HFpEF.
In conclusion, due to the robust body of literature
demonstrating prognostic utility as well as the ability to
accurately gauge disease severity and therapeutic eﬃ-
cacy, CPX is a well-established clinical assessment in
the HFrEF population. Evidence is beginning to
emerge indicating CPX may be equally valuable in
patients with HFpEF. The results of the present study
lend further support to this position by demonstrating
key CPX variables are equally reﬂective of pathophysi-
ology and thus disease severity in well-matched HFrEF
and HFpEF cohorts. Research should continue to
examine the value of CPX in the HFpEF population
to determine if support for utilization of this exercise
assessment as a clinical standard of care is warranted.
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